Resolor is the first of a new generation of selective, high-affinity 5-HT4 receptor agonists. The product was approved in the EU by the European Medicines Agency ("EMA") in October 2009 for the ...

TURNHOUT, Belgium, May 29 /PRNewswire/ -- Movetis today announced that the European Medicines Agency (EMeA) has accepted the Marketing Authorization Application (MAA) submission for RESOLOR(R) ...

Please provide your email address to receive an email when new articles are posted on . Results from a recent phase 3 study showed that Resolor is a safe, effective and well-tolerated treatment for ...

Quintiles today announced a strategic alliance with Movetis NV for commercialization of its new product, Resolor (prucalopride), in the U.K. and Germany. Under the alliance, Quintiles will execute a ...

BRUSSELS, Nov 20 (Reuters) - Belgian drugmaker Movetis said it could raise up to 112.4 million euros ($167 million) in an initial public offering to help fund the European launch of its Resolor ...

LONDON (Alliance News) - FTSE 100-listed pharmaceutical company Shire PLC said Wednesday that the European Medicines Agency has approved Resolor for the use in male adults for the treatment of chronic ...

Resolor (prucalopride), a new prescription drug for the treatment of chronic constipation in women, is now available in the UK. Resolor (prucalopride), a new prescription drug for the treatment of ...

NICE has granted approval for Resolor to be used by the NHS for treatment of certain trypes of chronic constipation The National Institure for Health and Clinical Excellence (NICE) has granted final ...

The latest set of opinions from the European Medicines Agency’s Committee for Medicinal Products for Human Use includes a number of extensions of indication and a recommendation for a new orphan drug.

Shire ( SHPGY) recently announced that it has entered into an agreement with Janssen Pharmaceutica N.V., a Johnson & Johnson ( JNJ) company, to acquire the rights to develop and commercialize Resolor ...

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced today that it has acquired the rights to develop and market Resolor ® (prucalopride) in the United States ...

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced today that it has acquired the rights to develop and market Resolor ® (prucalopride) in the United States ...